Metabolic syndrome and the risk of prostate cancer in finnish men: A population-based study

Cancer Epidemiology Biomarkers and Prevention

Volumn 13, Issue 10, 2004, Pages 1646-1650

  Laukkanen, Jari A ^a,b   Laaksonen, David E ^a,c   Niskanen, Leo ^c   Pukkala, Eero ^d   Hakkarainen, Anna ^a   Salonen, Jukka T ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b Savonlinna Central Hospital   (Finland)

^c KUOPIO UNIVERSITY HOSPITAL   (Finland)

^d FINNISH CANCER REGISTRY   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; CALCIUM; LINOLEIC ACID;

ADULT; AGE; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; CALCIUM INTAKE; CALORIC INTAKE; CANCER RISK; CONTROLLED STUDY; EPIDEMIC; FAT INTAKE; FINLAND; FITNESS; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OBESITY; POPULATION RESEARCH; PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT; RISK FACTOR; VITAMIN INTAKE;

FINLAND; HUMANS; INCIDENCE; LIFE STYLE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 4944223630     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Chokkalingam AP, Pollak M, Fillmore CM, et al. Insulin-like growth factors and prostate cancer: a population-based case-control study in China. Cancer Epidemiol Biomarkers Prev 2001;10:421-7.
2. Wolk A, Mantzoros CS, Andersson SO, et al. Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. J Natl Cancer Inst 1998;90:911-5.
3. Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002;288:2709-16.
4. Laaksonen DE, Lakka HM, Niskanen LK, Kaplan GA, Salonen JT, Lakka TA. Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am J Epidemiol 2002;156:1070-7.
5. Balkau B, Charles MA, Drivsholm T, et al. European Group for the Study of Insulin Resistance (EGIR). Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome. Diabetes Metab 2002;28:364-76.
6. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37:1595-607.
7. Vercelli M, Quaglia A, Marani E, Parodi S. Prostate cancer incidence and mortality trends among elderly and adult Europeans. Crit Rev Oncol Hematol 2000;35:133-44.
8. Finnish Cancer Registry. Cancer incidence in Finland. Cancer statistics of the National Research and Development Center for Welfare and Health. Cancer Society of Finland publication available at http://www.cancerregistry.fi/v2001/ v2000002oi.html; 2001.
9. Barnard RJ, Aronson WJ, Tymchuk CN, Ngo TH. Prostate cancer: another aspect of the insulin-resistance syndrome? Obes Rev 2002;3:303-8.
10. Smith GD, Gunnell D, Holly J. Cancer and insulin-like growth factor-I. A potential mechanism linking the environment with cancer risk. BMJ 2000;321:847-8.
11. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Willett WC. Height, body weight, and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 1997;6:557-63.
12. Potosky AL, Miller BA, Albertsen PC, Kramer BS. The role of increasing detection in the rising incidence of prostate cancer. JAMA 1995;273:548-52.
13. WHO. Definition, diagnosis and classification of diabetes mellitus and its complications: part 1: diagnosis and classification of diabetes mellitus. Vol. 52. Geneva: WHO; 1999.
14. Lakka HM, Lakka TA, Tuomilehto J, Sivenius J, Salonen JT. Hyperinsulinemia and the risk of cardiovascular death and acute coronary and cerebrovascular events in men: the Kuopio Ischemic Heart Disease Risk Factor Study. Arch Intern Med 2000;160:1160-8.
15. Salonen JT, Salonen R, Seppanen K, Rauramaa R, Tuomilehto J. HDL, HDL2, and HDL3 subfractions, and the risk of acute myocardial infarction. A prospective population study in eastern Finnish men. Circulation 1991;84:129-39.
16. Voutilainen S, Rissanen TH, Virtanen J, Lakka TA, Salonen JT. Low dietary folate intake is associated with an excess incidence of acute coronary events: the Kuopio Ischemic Heart Disease Risk Factor Study. Circulation 2001;103:2674-80.
17. Salonen JT, Kaplan GA. Socioeconomic conditions and ischemic heart disease. BMJ 1991;302:113-4.
18. Teppo L, Pukkala E, Lehtonen M. Data quality and quality control of a population-based cancer registry. Experience in Finland. Acta Oncol 1994;33:365-9.
19. Marchesani M, Hakkarainen A, Tuomainen TP, et al. New paraoxonase 1 polymorphism I102V and the risk of prostate cancer in Finnish men. J Natl Cancer Inst 2003;95:812-8.
20. Niskanen LK, Salonen JT, Nyyssonen K, Uusitupa MI. Plasma lipid peroxidation and hyperglycemia: a connection through hyperinsulinemia? Diabet Med 1995;12:802-8.
21. Chyou PH, Nomura AM, Stemmermann GN. A prospective study of weight, body mass index and other anthropometric measurements in relation to site-specific cancers. Int J Cancer 1994;57:313-7.
22. Andersson SO, Wolk A, Bergstrom R, et al. Body size and prostate cancer: a 20-year follow-up study among 135006 Swedish construction workers. J Natl Cancer Inst 1997;89:385-9.
23. Nilsen TI, Vatten LJ. Anthropometry and prostate cancer risk: a prospective study of 22,248 Norwegian men. Cancer Causes Control 1999;10:269-75.
24. Lee IM, Sesso HD, Paffenbarger RS Jr. A prospective cohort study of physical activity and body size in relation to prostate cancer risk (United States). Cancer Causes Control 2001;12:187-93.
25. Hsing AW, Chua S Jr, Gao YT, et al. Prostate cancer risk and serum levels of insulin and leptin: a population-based study. J Natl Cancer Inst 2001;93:783-9.
26. Hsing AW, Gao YT, Chua S Jr, Deng J, Stanczyk F.Z. Insulin resistance and prostate cancer risk. J Natl Cancer Inst 2003;95:67-71.
27. Stattin P, Bylund A, Rinaldi S, et al. Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study. J Natl Cancer Inst 2000;92:1910-7.
28. Chan JM, Stampfer MJ, Giovannucci E, et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998;279:563-6.
29. Shaneyfelt T, Husein R, Bubley G, Mantzoros CS. Hormonal predictors of prostate cancer: a meta-analysis. J Clin Oncol 2000;18:847-53.
30. Gronberg H. Prostate cancer epidemiology. Lancet 2003;361:859-64.
31. Parviainen MT, Salonen JT. Diet, blood pressure and hypertension. Br J Nutr 2000;83:S113-9.
32. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-50.
33. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. Diabetes Prevention Program Research Group. N Engl J Med 2002;346:393-403.
34. Laaksonen DE, Lakka HM, Salonen JT, Niskanen LK, Rauramaa R, Lakka TA. Low levels of leisure-time physical activity and cardiorespiratory fitness predict development of the metabolic syndrome. Diabetes Care 2002;25:1612-8.
35. Barnard RJ, Ngo TH, Leung PS, Aronson WJ, Golding LA. A low-fat diet and/or strenuous exercise alters the IGF axis in vivo and reduces prostate tumor cell growth in vitro. Prostate 2003;56:201-6.
36. Hartman TJ, Albanes D, Rautalahti M, et al. Physical activity and prostate cancer in the α-Tocopherol, β-Carotene (ATBC) Cancer Prevention Study (Finland). Cancer Causes Control 1998;9:11-8.
37. Comhaire FH. Andropause: hormone replacement therapy in the aging male. Eur Urol 2000;38:655-62.
38. Conroy RM, Pyorala K, Fitzgerald AP, et al. SCORE project group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003;24:987-1003.